#1 Ranked Children’s Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
There are many ways you can help children and their families get the care they need.
Caption: Advanced MRI images from the corpus callosum of the brain, showing bundles of nerve fibers, or axons.
Boston Children’s has the largest hospital-based basic neuroscience research enterprise in the United States. We also participate in a variety of clinical trials.
Active areas of investigation include developmental disorders, intellectual disability, autism, neuromuscular disorders, pain, epilepsy, neurometabolic disorders, eye-movement disorders, encephalopathy of prematurity, traumatic brain injury and more. The goal: to create better treatments.
Researchers in Neurology at Boston Children's are fortunate to have cutting edge tools and facilities close at hand to aid discovery. These include:
The Department of Neurology’s research program is focused on the developing brain and seeks to integrate clinical and basic neuroscience. In addition to research housed in the Department, we work closely with:
Boston Children’s participates in a variety of drug trials, many of them initiated here, as well as clinical studies that track patients to continuously improve our care. We are also testing innovations such bracelets for detecting seizures or hand movements characteristic of neurologic disorders and conduct genetic research to help us better understand rare neurologic conditions.
Here are some examples of our clinical research and innovation:
Synapse development and brain plasticity
Several laboratories at Boston Children’s are investigating how connections or synapses between nerve cells in the developing brain are established, what enables connections to change over time and how synapse development can go awry to cause disease. The labs of Michela Fagiolini, PhD and Chinfei Chen, MD, for example, are using mouse models of Rett syndrome and the visual system to better understand this process. The lab of Beth Stevens, PhD, has revealed the role of microglia and immune molecules in synapse formation and elimination and has shown its relevance to normal brain development as well as disorders like schizophrenia and Alzheimer’s disease.
Brain connectivity and signaling
Several Boston Children’s labs, including those of Mustafa Sahin, MD, PhD, and Xi He, PhD, have investigated how biochemical signals regulate the process of circuit development in the brain. Sahin’s lab focuses on this question by studying tuberous sclerosis, a condition that frequently includes autism, through mouse models and structural brain imaging, aided by computational techniques. Takao Hensch, PhD, studies brain connectivity and the role played by specific “critical periods” in brain development.
The lab of Clifford Woolf, PhD, is investigating new ways to selectively inhibit pain nerve fibers, or axons, and is modeling pain in neurons made from patients’ skin cells.
Several labs, including those of Zhigang He, PhD, and Larry Benowitz, PhD, are looking for ways to regenerate nerve fibers in the central nervous system that could someday help patients with optic nerve trauma, glaucoma or spinal cord injury.
Precision medicine for brain tumors
The lab of neurologist-in-chief Scott Pomeroy, MD, PhD, is applying advanced genetics techniques, including genomic sequencing and genome-wide expression studies, to define biologically and clinically distinct subtypes of tumors such as medulloblastoma. Many of the mutations he’s identified are in epigenetic regulatory molecules. Based on his findings, the Children’s Oncology Group is now conducting next-generation clinical trials using molecular markers to stratify brain tumor patients’ disease risk.
Prenatal risk factors and brain development
In the ongoing Extremely Low Gestational Age Newborn (ELGAN) study, Alan Leviton, MD, and colleagues have identified inflammation and being born small for gestational age as risk factors for cerebral palsy.
From our origins in the 1920s, the Department of Neurology has been pushing for answers. Our first child neurologist-in-chief, Bronson Crothers, MD, began probing the mechanisms of cerebral palsy in the 1950s, and Randolph Byers, MD, who followed in his footsteps, was the first to identify lead poisoning as a cause of learning problems in the 1940s. William Lennox, MD, helped classify childhood epilepsies in the 1920s and went on to define their neurophysiology and genetics. Read more about our history.
We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”